atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
Stressed about finding the right iOS development partner?
@beetroot_se have done the legwork. Their latest blog post spotlights top iOS app developers across different regions and offers key tips for your search.
Read more here.
Digostics, a UK-based diabetes home-testing provider, who graduated from our NHS Market Access Accelerator programme in 2022 have partnered with Medway NHS Foundation Trust to transform local gestational diabetes screening, by offering world-first home oral glucose tolerance testing (OGTT) technology to all…
Attendees
Sponsors and
Exhibitors
Agenda
Webinars
Contact us